Deleted In Liver Cancer 3 (Dlc-3), A Novel Rho Gtpase-Activating Protein Gene, Inhibits Cell Growth And Is Down-Regulated In Cancer
Marian E. Durkin,Veronika Ullmannova,Ming Guan,Nicolae C. Popescu
IF: 11.2
2006-01-01
Cancer Research
Abstract:2569 Two members of the deleted in liver cancer gene family, DLC-1 and DLC-2, are emerging as bona fide tumor suppressor genes that can inhibit cancer cell growth and motility. DLC-1 and DLC-2 are approximately 120 kDa polypeptides that serve as GTPase activating proteins (GAPs) for members of the Rho family of small GTPases, converting them to the inactive, GDP-bound form. In this report, we characterize a gene on chromosome Xq13 that encodes DLC-3 (also known as STARD8), a novel member of the DLC family. Two DLC-3 transcripts that differ at the 5’ end have been identified. DLC-3a encodes a polypeptide of 1103 amino acids that is around 50% identical in amino acid sequence to DLC-1/DLC-2 and has a similar structural organization, consisting of an N- terminal sterile alpha motif (SAM) domain, a serine-rich domain, the RhoGAP domain, and a C-terminal lipid binding START domain. A second isoform (DLC-3b, KIAA0189) appears to arise from the use of an alternative promoter and would yield a protein lacking the SAM domain. The high degree of sequence identity between the RhoGAP domain of DLC-3 and those of DLC-1 and DLC-2, which were shown to act as GAPs for RhoA and Cdc42, suggests that DLC-3 may have similar activity. The DLC-3 gene is widely expressed, overlapping with the distribution of the DLC-1 and DLC-2 transcripts. DLC-3 mRNA levels were low or absent in a significant number of breast, ovarian, liver, and prostate cancer cell lines. Using a Cancer Profiling Array (Clontech) to compare DLC-3 expression in matched tumor and normal human tissues, a decrease or loss of DLC-3 mRNA was observed in kidney, lung, ovarian, uterine, and breast cancer samples. By RT-PCR, down-regulation of DLC-3 was detected in primary prostate carcinomas and benign prostate hyperplasia relative to normal prostate tissue. Transfection of MCF-7 breast cancer cells and 22Rv1 prostate cancer cells with a DLC-3a expression vector suppressed cell growth and colony formation. These results indicate that DLC-3 may play a role in the control of cell proliferation, and its deregulation may contribute to breast and prostate tumorigenesis.